Cyclosporine A inhibits breast cancer cell growth by downregulating the expression of pyruvate kinase subtype M2

International Journal of Molecular Medicine

Volumn 30, Issue 2, 2012, Pages 302-308

  Jiang, Kai ^a,b   He, Baoming ^c   Lai, Lihua ^a   Chen, Qingyun ^a   Liu, Yang ^a   Guo, Qingming ^a   Wang, Qingqing ^a  

^a ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b Zhejiang Provincial Tongde Hospital   (China)

^c 309TH HOSPITAL OF PLA   (China)

Author keywords

Adenosine triphosphate; Breast cancer cells; Cyclosporine A; Pyruvate kinase M2

Indexed keywords

ADENOSINE TRIPHOSPHATE; CYCLOSPORIN A; PYRUVATE KINASE; PYRUVATE KINASE M2; UNCLASSIFIED DRUG;

ARTICLE; BREAST CARCINOMA; CANCER CELL CULTURE; CANCER INHIBITION; CELL DEATH; CELL PROLIFERATION; CELL STRAIN MCF 7; CELL VIABILITY; CONTROLLED STUDY; DOSE RESPONSE; DOWN REGULATION; ENZYME ACTIVITY; FLUORESCENCE ACTIVATED CELL SORTING; HUMAN; HUMAN CELL; HUMAN TISSUE; MITOCHONDRIAL MEMBRANE POTENTIAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SYNTHESIS;

BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; CYCLOSPORINE; DOWN-REGULATION; ENZYME ACTIVATION; ENZYME INHIBITORS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; PYRUVATE KINASE;

EID: 84863552719     PISSN: 11073756     EISSN: 1791244X     Source Type: Journal    
DOI: 10.3892/ijmm.2012.989     Document Type: Article

References (33)

1. Warburg O: On the origin of cancer cells. Science 123: 309-314, 1956.
2. Mazurek S, Boschek CB, Hugo F, et al: Pyruvate kinase type M2 and its role in tumor growth and spreading. Semin Cancer Biol 15: 300-308, 2005.
3. Anastasiou D, Poulogiannis G, Asara JM, et al: Inhibition of pyruvate kinase M2 by reactive oxygen species contributes to cellular antioxidant responses. Science 334: 1278-1283, 2011.
4. Goldberg MS and Sharp PA: Pyruvate kinase M2-specific siRNA induces apoptosis and tumor regression. J Exp Med: Jan 23, 2012 (Epub ahead of print). doi: 10.1084/jem.20111487.
5. Yang W, Xia Y, Ji H, et al: Nuclear PKM2 regulates beta-catenin transactivation upon EGFR activation. Nature 480: 118-122, 2011.
6. Christofk HR, Vander Heiden MG, Harris MH, et al: The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth. Nature 452: 230-233, 2008.
7. Christofk HR, Vander Heiden MG, Wu N, et al: Pyruvate kinase M2 is a phosphotyrosine-binding protein. Nature 452: 181-186, 2008.
8. Altenberg B and Greulich KO: Genes of glycolysis are ubiquitously overexpressed in 24 cancer classes. Genomics 84: 1014-1020, 2004.
9. Saeki T, Ueda K, Tanigawara Y, et al: Human P-glycoprotein transports cyclosporin A and FK506. J Biol Chem 268: 6077-6080, 1993.
10. Tan B, Piwnica-Worms D and Ratner L: Multidrug resistance transporters and modulation. Curr Opin Oncol 12: 450-458, 2000.
11. Englund G, Hallberg P, Artursson P, et al: Association between the number of coadministered P-glycoprotein inhibitors and serum digoxin levels in patients on therapeutic drug monitoring. BMC Med 2: 8, 2004.
12. Carcel-Trullols J, Torres-Molina F, Araico A, et al: Effect of cyclosporine A on the tissue distribution and pharmacokinetics of etoposide. Cancer Chemother Pharmacol 54: 153-160, 2004.
13. Xia CQ, Liu N, Miwa GT, et al: Interactions of cyclosporin A with breast cancer resistance protein. Drug Metab Dispos 35: 576-582, 2007.
14. Berthon P, Pancino G, de Cremoux P, et al: Characterization of normal breast epithelial cells in primary cultures: differentiation and growth factor receptors studies. In Vitro Cell Dev Biol 28A: 716-724, 1992.
15. Wang QQ, Li H, Oliver T, et al: Integrin beta 1 regulates phagosome maturation in macrophages through Rac expression. J Immunol 180: 2419-2428, 2008.
16. Liu Y, Chen Q, Song Y, et al: MicroRNA-98 negatively regulates IL-10 production and endotoxin tolerance in macrophages after LPS stimulation. FEBS Lett 585: 1963-1968, 2011.
17. Dombrauckas JD, Santarsiero BD and Mesecar AD: Structural basis for tumor pyruvate kinase M2 allosteric regulation and catalysis. Biochemistry 44: 9417-9429, 2005.
18. Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 25: 402-408, 2001.
19. Larson EL, Aiello AE, Gomez-Duarte C, et al: Bioluminescence ATP monitoring as a surrogate marker for microbial load on hands and surfaces in the home. Food Microbiol 20: 735-739, 2003.
20. Ishaque A and Al-Rubeai M: Use of intracellular pH and annexin-V flow cytometric assays to monitor apoptosis and its suppression by bcl-2 over-expression in hybridoma cell culture. J Immunol Methods 221: 43-57, 1998.
21. Leist M, Single B, Castoldi AF, et al: Intracellular adenosine triphosphate (ATP) concentration: a switch in the decision between apoptosis and necrosis. J Exp Med 185: 1481-1486, 1997.
22. Garber K: Energy deregulation: licensing tumors to grow. Science 312: 1158-1159, 2006.
23. Tani K, Yoshida MC, Satoh H, et al: Human M2-type pyruvate kinase: cDNA cloning, chromosomal assignment and expression in hepatoma. Gene 73: 509-516, 1988.
24. Yamada K and Noguchi T: Regulation of pyruvate kinase M gene expression. Biochem Biophys Res Commun 256: 257-262, 1999.
25. Li R, Liu J, Xue H, et al: Diagnostic value of fecal tumor M2-pyruvate kinase for CRC screening: A systematic review and meta-analysis. Int J Cancer: Jan 19, 2012 (Epub ahead of print). doi: 10.1002/ijc.27442.
26. Schneider J, Velcovsky HG, Morr H, et al: Comparison of the tumor markers tumor M2-PK, CEA, CYFRA 21-1, NSE and SCC in the diagnosis of lung cancer. Anticancer Res 20: 5053-5058, 2000.
27. Schneider J and Schulze G: Comparison of tumor M2-pyruvate kinase (tumor M2-PK), carcinoembryonic antigen (CEA), carbohydrate antigens CA 19-9 and CA 72-4 in the diagnosis of gastrointestinal cancer. Anticancer Res 23: 5089-5093, 2003.
28. Buchholz M, Schatz A, Wagner M, et al: Overexpression of c-myc in pancreatic cancer caused by ectopic activation of NFATc1 and the Ca2+/calcineurin signaling pathway. EMBO J 25: 3714-3724, 2006.
29. Masuo T, Okamura S, Zhang Y, et al: Cyclosporine A inhibits colorectal cancer proliferation probably by regulating expression levels of c-Myc, p21(WAF1/CIP1) and proliferating cell nuclear antigen. Cancer Lett 285: 66-72, 2009.
30. Wooll JO, Friesen RH, White MA, et al: Structural and functional linkages between subunit interfaces in mammalian pyruvate kinase. J Mol Biol 312: 525-540, 2001.
31. Gallimore A and Godkin A: Regulatory T cells and tumour immunity - observations in mice and men. Immunology 123: 157-163, 2008.
32. Curiel TJ, Coukos G, Zou L, et al: Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 10: 942-949, 2004.
33. Wu Y, Borde M, Heissmeyer V, et al: FOXP3 controls regulatory T cell function through cooperation with NFAT. Cell 126: 375-387, 2006.